respiratory
COPD

No evidence LABA/ICS inhalers raise risk of CV events in COPD: SUMMIT


Inhalers used to treat COPD carry no excess cardiovascular risk – a finding that could finally quash long-held concerns about use of the drugs in COPD patients who also have cardiovascular disease. Researchers from the SUMMIT trial – the largest COPD outcome trial and the first to specifically enrol patients with, or at greater risk ...

Already a member?

Enter your email to keep reading.


OR